CoChat

A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers

Nguyen, Nhan T., Vendrell, Julie A., Poulard, Coralie, Győrffy, Balázs, Goddard-Léon, Sophie, Bièche, Ivan, Corbo, Laura, Le Romancer, Muriel, Bachelot, Thomas, Treilleux, Isabelle, Cohen, Pascale A. · 2014 · Molecular Oncology
Cited by 35

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

We aimed at highlighting the role of ZNF217, a Krüppel‐like finger protein, in Estrogen Receptor‐α (ERα)‐positive (ER+) and luminal breast cancers. Here we report for the first time that ZNF217 and ERα proteins bind to each other in both breast cancer cells and breast tumour samples, via the ERα hinge domain and the ZNF217 C‐terminal domain. ZNF217 enhances the recruitment of ERα to its estrogen response elements (ERE) and the ERα‐dependent transcription of the GREB1 estrogen‐regulated gene. The prognostic power of ZNF217 mRNA expression levels is most discriminatory in breast cancers classified with a “good prognosis”, particularly the Luminal‐A subclass. A new immunohistochemistry ZNF217 index, based on nuclear and cytoplasmic ZNF217 staining, also allowed the identification of intermediate/poor relapse‐free survivors in the Luminal‐A subgroup. ZNF217 confers tamoxifen resistance in ER+ breast cancer cells and is a predictor of relapse under endocrine therapy in patients with ER+ breast cancer. ZNF217 thus allows the re‐stratification of patients with ER+ breast cancers considered as cancers with good prognosis where no other biomarkers are currently available and widely used. Here we propose a model in ER+ breast cancer where ZNF217‐driven aggressiveness incorporates ZNF217 as a positive enhancer of ERα direct genomic activity and where ZNF217 possesses its highest discriminatory prognostic value.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2014.05.013

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 65

  1. 10.1038/onc.2009.151 · DOI
  2. Badia E., 2000, Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling, Cancer Res, 60, 4130
  3. 10.4161/epi.4.2.7953 · DOI
  4. 10.1200/JCO.2005.03.3845 · DOI · Paper page
  5. 10.1200/JCO.2009.26.3756 · DOI · Paper page
  6. 10.1158/1078-0432.CCR-07-1833 · DOI · Paper page
  7. 10.1073/pnas.95.15.8703 · DOI · Paper page
  8. 10.1101/gr.GR1743R · doi:10.1101/gr.gr1743r · Paper page
  9. 10.1038/sj.onc.1210126 · DOI
  10. 10.1200/JCO.2010.31.2835 · DOI · Paper page
  11. 10.1101/gad.1061803 · DOI · Paper page
  12. 10.1016/j.ejca.2006.11.018 · DOI
  13. 10.1074/jbc.M114.553511 · DOI
  14. 10.1210/me.16.5.947 · doi:10.1210/me.16.5.947
  15. 10.1002/ijc.24750 · DOI
  16. 10.1007/s10549-012-2148-8 · DOI
  17. 10.1159/000328054 · DOI · Paper page
  18. 10.1093/annonc/mdt303 · DOI · Paper page
  19. 10.1093/annonc/mdr304 · DOI · Paper page
  20. 10.1093/annonc/mds586 · DOI · Paper page
  21. 10.1002/ijc.24696 · DOI
  22. 10.1007/s10549-011-1676-y · DOI
  23. 10.1007/s10549-008-0242-8 · DOI
  24. 10.1007/s10549-009-0580-1 · DOI
  25. 10.1186/1471-2164-7-96 · DOI · Paper page
  26. 10.1093/hmg/ddi352 · DOI
  27. 10.1074/jbc.M611752200 · DOI · Paper page
  28. 10.1038/onc.2010.289 · DOI
  29. 10.1002/ijc.28741 · DOI
  30. 10.1016/j.steroids.2010.01.013 · DOI
  31. 10.1186/1471-2407-6-245 · DOI
  32. 10.1002/ijc.22300 · DOI
  33. 10.1158/2159-8290.CD-12-0093 · DOI
  34. 10.1371/journal.pone.0046410 · DOI
  35. 10.1186/1471-2164-9-239 · DOI · Paper page
  36. 10.1210/me.2013-1376 · DOI
  37. 10.1158/1078-0432.CCR-10-1282 · DOI · Paper page
  38. Nonet G.H., 2001, The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells, Cancer Res, 61, 1250
  39. 10.1200/JCO.2008.18.1370 · DOI · Paper page
  40. 10.1038/35021093 · DOI · Paper page
  41. 10.1186/bcr1399 · DOI · Paper page
  42. 10.1093/oxfordjournals.epirev.a036102 · DOI · Paper page
  43. 10.4149/neo_2010_04_325 · DOI
  44. 10.1002/emmm.201201615 · DOI
  45. 10.1128/MCB.00680-06 · DOI · Paper page
  46. Quinlan K.G., 2007, Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad, Biochim. Biophys. Acta, 1775, 333
  47. 10.1002/cncr.26598 · DOI
  48. 10.1210/mend-2-12-1157 · DOI · Paper page
  49. 10.1210/me.2005-0042 · DOI · Paper page
  50. 10.1073/pnas.191367098 · DOI · Paper page
  51. 10.1073/pnas.0932692100 · DOI · Paper page
  52. 10.1073/pnas.68.7.1542 · DOI · Paper page
  53. 10.1016/j.molcel.2008.03.022 · DOI · Paper page
  54. 10.1016/j.mce.2008.07.018 · doi:10.1016/j.mce.2008.07.018
  55. 10.1128/MCB.00246-08 · DOI
  56. 10.1186/1476-4598-9-291 · DOI
  57. 10.1210/me.2007-0242 · DOI
  58. 10.1677/erc.1.00899 · DOI
  59. 10.1038/sj.onc.1210269 · DOI
  60. 10.1677/jme.0.0320397 · DOI
  61. 10.1186/bcr2158 · doi:10.1186/bcr2158
  62. 10.1158/0008-5472.CAN-11-3095 · DOI
  63. 10.1002/ijc.28182 · DOI
  64. 10.1158/0008-5472.CAN-05-0486 · DOI · Paper page
  65. 10.1093/nar/gkl764 · DOI

Cited by

Metadata

Authors
Nguyen, N. T., Vendrell, J. A., Poulard, C., Győrffy, B., Goddard-Léon, S., Bièche, I., Corbo, L., Le Romancer, M., Bachelot, T., Treilleux, I., & Cohen, P. A.
Venue
Molecular Oncology
Publisher
Wiley
Published
2014-06-10
Volume
8
Issue
8
Pages
1441-1457
ISSN
  • 1574-7891
  • 1878-0261
Cited by
35
References
1
Language
en
Funders
  • PRES/Lyon Science Transfert
  • Cancéropôle Lyon Auvergne Rhône-Alpes
  • the Department of the Rhône
  • Ligue Nationale Contre le Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.